Today: 11 June 2026
Browse Category

NASDAQ:PAY 2 January 2026 - 4 January 2026

Paymentus stock ends first 2026 session down nearly 10% — what’s behind the sudden drop?

Paymentus stock ends first 2026 session down nearly 10% — what’s behind the sudden drop?

Paymentus Holdings shares fell 9.9% to $28.47 on Friday, trading nearly double their average volume and triggering a Nasdaq “oversold” alert. The drop outpaced Bill Holdings, down 7.3%, while Affirm and Shift4 slipped about 0.5% each. The Dow and S&P 500 closed higher. Investors are focused on upcoming U.S. jobs and inflation data for signals on interest rates.
4 January 2026
·

Stock Market Today

  • Banco BPM Stock Valuation Reviewed as Shares Rise Amid Earnings Momentum
    June 11, 2026, 11:13 AM EDT. Banco BPM (BIT:BAMI) has posted robust share price gains of 8.85% in the past month and 51.01% over the last year, driven by strong earnings with revenue of €5.42 billion and net income of €2.05 billion. Despite recent appreciation, analysts see the stock as slightly overvalued at a consensus fair value of €13.71, below the current price of €14.03. Banco BPM trades at a price-to-earnings (P/E) ratio of 10.3 times, below European bank peers at 11.3 times, suggesting some valuation cushion. However, risks such as increased fintech competition and challenges in cost efficiencies remain. Investor focus is on whether current momentum fully reflects growth expectations or leaves room for further upside.

Latest articles

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

11 June 2026
TOVX soared 74.6% to $0.4252 after Theriva Biologics published Phase 1 VCN-01 data showing survival and biomarker signals in head-and-neck cancer, but the jump was not due to drug approval or revenue; investors face ongoing financing, dilution, and clinical-trial execution risks, with the company’s cash runway only into Q1 2027 and substantial doubt about its ability to continue as a going concern without new capital.
Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

11 June 2026
Trulieve began NYSE trading as TRLV this week after moving from OTC/CSE, authorized a buyback of up to $50 million or 8.5 million shares, and closed its first NYSE session at $11.50, down 0.43%, before trading near $11.78 early Thursday, as investors weigh whether the uplisting and buyback will boost demand amid ongoing federal cannabis policy uncertainty.
Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

11 June 2026
Propanc Biopharma shares soared as much as 392% after authorizing up to $5 million in stock buybacks—exceeding its prior $3.1 million equity value—even as it reported just $443,702 in cash and flagged going-concern risks, with investors now focused on whether its lead cancer drug PRP will advance to a planned Phase 1b trial this year.
Go toTop